Neursantys, Inc.

What Neursantys, Inc. does

Neursantys, Inc. is a privately-held bioelectronics company founded in 2016 and headquartered in Chicago, IL, with additional offices in Calgary, Canada and Cupertino, CA. The company has developed NEURVESTA, a non-invasive electrical vestibular stimulation (EVS) platform designed to detect and treat neurophysiological impairment associated with balance dysfunction. The platform combines wearable bioelectronic medical devices, the Phybrata inertial sensor licensed from PROTXX, proprietary EVS waveforms, and machine-learning-driven biomarker analytics in a closed-loop architecture that senses vestibular response and adapts stimulation in real time.

Neursantys targets multiple end markets with a single underlying technology: senior living providers (fall prevention), clinical neurologists, rehabilitation providers (Multiple Sclerosis, head injury, stroke recovery), and space medicine researchers (microgravity adaptation). The company has built a research and validation ecosystem spanning Mayo Clinic, McGill University, the University of Calgary, the National Research Council of Canada, and PROTXX, and has published clinical evidence in peer-reviewed venues including Medical Devices: Evidence & Research (March 2026). US Patent #12,599,316 was awarded in January 2026, covering the core systems for detecting and treating neurophysiological impairment via vestibular stimulation.

The company pursues an enterprise field sales go-to-market model, driving adoption through IRB-approved research studies and clinical pilots rather than traditional direct-to-consumer channels. Distribution is supplemented by partnerships such as Jali Medical. Named pilot customers include United Active Living, Caring Hands Caregivers, and Forum at Rancho San Antonio. Pricing and contract structures are not publicly disclosed. To date, capital has been sourced primarily through non-dilutive grants — including a $350K CAD Canadian Space Agency award in 2023, an a2 Collective Pilot Award in 2024, and mHUB support in 2021 — with no traditional equity financing disclosed and headcount reported at 1–10 employees.

Name

Neursantys, Inc.

Legal name

Neursantys Inc.

Website

https://neursantys.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Neursantys is a bioelectronics company developing NEURVESTA, a non-invasive electrical vestibular stimulation platform that combines wearable sensing with machine learning to assess and treat balance impairment, serving senior living, neurology, rehabilitation, and space medicine markets.

Ownership category

akta.pro rank

Product category

Bioelectronic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC)

Keywords

• Neuromotor bioelectronic devices
• Vestibular neurostimulation therapy
• Wearable medical devices
• Balance restoration treatment
• Non-invasive electrical stimulation

Headquarters

HQ city

Calgary

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. NEURVESTA Device Sales: Sale of the NEURVESTA bioelectronic balance restoration device to research institutions, clinical facilities, and senior living communities for approved research studies and clinical pilots.
2. Clinical Research Collaborations: Revenue from R&D collaborations with academic and clinical partners including universities, research institutions, and healthcare systems for pilot deployments and clinical studies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Neursantys develops and sells the NEURVESTA bioelectronics platform, a wearable medical device that delivers non-invasive electrical vestibular stimulation (EVS) to treat age-related balance decline and other neuromotor conditions. The platform combines proprietary EVS waveforms, the licensed Phybrata neurophysiological impairment sensor, and machine learning models to quantify balance impairment and deliver personalized treatment (three 20-minute sessions per week for 6 weeks). It is currently sold to senior living communities, clinical researchers, rehabilitation providers, and space medicine researchers under IRB-approved research studies and clinical pilots.

Product overview

Neursantys offers the NEURVESTA bioelectronics platform as its flagship core product—a wearable medical device that delivers non-invasive electrical vestibular stimulation (EVS) to treat age-related balance decline and other neuromotor conditions. The platform combines proprietary EVS waveforms developed through their bioelectronic treatment discovery technology with phybrata neurophysiological impairment sensors to enable personalized treatment protocols and real-time assessment of patient responses to stimulation parameters.

Differentiator

Problem solved

Functional benefit

Brands

• NEURVESTA: First bioelectronics platform enabling discovery and delivery of treatments for multiple neuromotor conditions. Delivers non-invasive electrical stimulation of the vestibular system (EVS) for age-related balance decline.
• Phybrata

Products and services

• NEURVESTA Bioelectronics Platform NEURVESTA is a wearable bioelectronic medical device that delivers non-invasive electrical vestibular stimulation (EVS) treatments for age-related balance decline and other neuromotor conditions. It uses proprietary EVS waveforms together with the Phybrata neurophysiological impairment sensor and machine learning models to provide neuroplastic restoration of disrupted balance through three 20-minute sessions per week for six weeks, and is currently sold to senior living communities, clinical research institutions, rehabilitation providers, and space medicine researchers under IRB-approved research studies and clinical pilots.

Quantifiable outcome

• 35% of U.S. adults aged 40+ (60 million) affected by balance impairments
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• McGill UniversitycoreStrategic or Co-development Partner · 13 August 2025Collaboration to study neuromotor development from childhood through adolescence, combining Neursantys' Phybrata diagnostics with McGill's neuroscience research capabilities.
• National Research Council of CanadacoreStrategic or Co-development Partner · 13 August 2025Collaborative research partnership to study neuromotor and cognitive development, with researchers presenting at CNS 2026 on associations between neuromotor and cognitive development.
• Caring Hands CaregiverscoreStrategic or Co-development Partner · 12 March 2025Partnership to pilot bioelectronic balance restoration for senior living communities, combining Neursantys' NEURVESTA technology with Caring Hands' caregiver network and senior care expertise.
• Health Everywhere HubminorStrategic or Co-development Partner · 1 January 2025Collaboration with Mount Royal University and University of Calgary showcased at Alberta's Health Everywhere Hub to help older Albertans restore and maintain balance.
• Synaptic Neuro RehabilitationcoreStrategic or Co-development Partner · 1 January 2024Partnership with University of Calgary to pilot groundbreaking bioelectronic treatment for multiple sclerosis using the NEURVESTA platform.
• Cortex DesignminorImplementation/ SI/ Consulting Partner · 1 January 2024Development partnership with Cortex Design for NEURVESTA bioelectronics platform industrial design and product development.
• Jali MedicalcoreChannel Partner/ Reseller/ Distributor · 1 September 2023Distribution and showcase partnership for NEURVESTA platform at major neuroscience conferences including SfN 2024 and SfN 2025.
• Mayo CliniccoreStrategic or Co-development Partner · 1 January 2022Know-how agreement with Mayo Clinic for technology and clinical expertise exchange in neurophysiological treatment development.
• PROTXXcoreTechnology or Integration · 1 January 2021Licensed Phybrata sensor technology from PROTXX for wearable neuroprosthetic device development. Phybrata sensing technology quantifies human body position, motion, and orientation to assess neurophysiological impairment.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• PROTXX: PROTXX developed the Phybrata wearable neurophysiological sensor that Neursantys licenses. Both companies target wearable assessment and treatment of neurophysiological impairment including balance disorders, making PROTXX the most direct technology peer even though it is also a licensor.
• Scion NeuroStim: Scion NeuroStim develops non-invasive electrical stimulation devices targeting vestibular pathways for vertigo and balance disorders. Directly comparable to Neursantys in modality (neurostimulation), target indication (vestibular dysfunction), and non-invasive wearable delivery.
• Otolith Labs: Otolith Labs is developing a wearable headband that delivers vestibular stimulation to treat vertigo and motion sickness. Overlaps with Neursantys in target indication (vestibular disorders), non-invasive modality, and wearable form factor aimed at consumer and clinical users.
• Cala Health: Cala Health makes FDA-cleared wearable neuromodulation devices (TAPS therapy) for essential tremor and other neurological conditions. Comparable as a wearable non-invasive neurostimulation platform targeting chronic neurological indications and progressing toward consumer/at-home use.
• ElectroCore: ElectroCore develops non-invasive vagus nerve stimulation (nVNS) devices for multiple neurological and inflammatory conditions. Similar business model of platform-based non-invasive bioelectronic medicine targeting conditions with limited treatment options.

Emerging players

• Elidah Medical: Elidah Medical (ELITONE) makes a wearable electrical stimulation device for women's health. Comparable in non-invasive wearable bioelectronic modality and consumer-targeted hardware distribution, though serving a different therapeutic indication.
• Lively (Tunstall): Lively (acquired by Tunstall) provides wearable personal-emergency-response and fall-detection devices aimed at seniors. Comparable in senior-living customer base, focus on fall prevention/risk reduction, and AgeTech go-to-market motion, though without a therapeutic intervention component.

Broad incumbents

• Cochlear Limited: Cochlear is the leading implantable hearing solutions company and is actively developing vestibular implant technologies for balance disorders. Represents the dominant incumbent in implantable vestibular/neurological intervention against which non-invasive approaches like Neursantys's must compete.
• Medtronic: Medtronic is a global leader in neuromodulation (deep brain, spinal cord, sacral nerve stimulation). Represents the large incumbent that could enter or absorb vestibular/balance indications with the capital and payer infrastructure Neursantys lacks.
• Abbott (Neuromodulation): Abbott's Neuromodulation division offers spinal cord and dorsal root ganglion stimulation. Comparable as a major medtech incumbent with the capital, regulatory muscle, and clinical-sales infrastructure to expand into adjacent neuromodulation indications including balance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neursantys

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neursantys, Inc.